Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Inclusion Criteria:

   - Must have histologically or cytologically confirmed adenocarcinoma of the prostate

   - Progressed on androgen deprivation therapy (ADT) and at least one prior secondary
   hormonal therapy approved for castration-resistant prostate cancer (CRPC)

   - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Exclusion Criteria:

   - Prior treatment with an androgen receptor (AR) degrader

   - Concurrent malignancy (present during screening) requiring treatment or history of
   prior malignancy active within 1 year prior to the first dose of IP

   - Clinically significant venous thromboembolism within 3 months prior to the first dose
   of IP

   - Any significant medical condition, such as uncontrolled infection, laboratory
   abnormality, or psychiatric illness

Other protocol-defined inclusion/exclusion criteria apply